Contineum Therapeutics, Class Stock Performance
| CTNM Stock | 12.41 0.27 2.13% |
Contineum Therapeutics, has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.45, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Contineum Therapeutics,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding Contineum Therapeutics, is expected to be smaller as well. Contineum Therapeutics, right now shows a risk of 4.02%. Please confirm Contineum Therapeutics, semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if Contineum Therapeutics, will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Contineum Therapeutics, Class are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Contineum Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2026. ...more
Actual Historical Performance (%)
One Day Return (2.13) | Five Day Return 5.71 | Year To Date Return (14.30) | Ten Year Return (19.42) | All Time Return (19.42) |
1 | Live market analysis of Contineum Therapeutics Inc. - July 2025 Volume Fast Gaining Stock Reports - newser.com | 10/31/2025 |
2 | Why Contineum Therapeutics Inc. stock could see breakout soon - 2025 Trading Recap Technical Entry and Exit Alerts - newser.com | 11/05/2025 |
3 | Royal Bank Of Canada Cuts Contineum Therapeutics Price Target to 22.00 | 11/21/2025 |
4 | Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference | 11/24/2025 |
5 | Contineum Therapeutics, Inc. institutional owners may be pleased with recent gains after 16 percent loss over the past year | 12/09/2025 |
6 | Contineum Therapeutics, Inc. added to NASDAQ Biotechnology Index - marketscreener.com | 12/22/2025 |
7 | Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - MSN | 12/26/2025 |
| Begin Period Cash Flow | 15.5 M | |
| Total Cashflows From Investing Activities | -69.7 M |
Contineum | Build AI portfolio with Contineum Stock |
Contineum Therapeutics, Relative Risk vs. Return Landscape
If you would invest 1,175 in Contineum Therapeutics, Class on September 30, 2025 and sell it today you would earn a total of 66.00 from holding Contineum Therapeutics, Class or generate 5.62% return on investment over 90 days. Contineum Therapeutics, Class is currently generating 0.1667% in daily expected returns and assumes 4.0207% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Contineum, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Contineum Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Contineum Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Contineum Therapeutics, Class, and traders can use it to determine the average amount a Contineum Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0415
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CTNM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Contineum Therapeutics, is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Contineum Therapeutics, by adding it to a well-diversified portfolio.
Contineum Therapeutics, Fundamentals Growth
Contineum Stock prices reflect investors' perceptions of the future prospects and financial health of Contineum Therapeutics,, and Contineum Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Contineum Stock performance.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 276.42 M | ||||
| Shares Outstanding | 30.45 M | ||||
| Price To Book | 2.51 X | ||||
| Price To Sales | 11.15 X | ||||
| EBITDA | (42 M) | ||||
| Net Income | (42.26 M) | ||||
| Total Debt | 6.26 M | ||||
| Book Value Per Share | 6.18 X | ||||
| Cash Flow From Operations | (32.84 M) | ||||
| Earnings Per Share | (2.25) X | ||||
| Market Capitalization | 453.33 M | ||||
| Total Asset | 212.85 M | ||||
| Retained Earnings | (117.4 M) | ||||
| Working Capital | 196.41 M | ||||
About Contineum Therapeutics, Performance
By examining Contineum Therapeutics,'s fundamental ratios, stakeholders can obtain critical insights into Contineum Therapeutics,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Contineum Therapeutics, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.21) | (0.20) |
Things to note about Contineum Therapeutics, performance evaluation
Checking the ongoing alerts about Contineum Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Contineum Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Contineum Therapeutics, had very high historical volatility over the last 90 days | |
| Net Loss for the year was (42.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Contineum Therapeutics, generates negative cash flow from operations | |
| Contineum Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| About 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - MSN |
- Analyzing Contineum Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Contineum Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Contineum Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Contineum Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Contineum Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Contineum Therapeutics,'s stock. These opinions can provide insight into Contineum Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Contineum Therapeutics, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Contineum Therapeutics,. If investors know Contineum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Contineum Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Contineum Therapeutics, is measured differently than its book value, which is the value of Contineum that is recorded on the company's balance sheet. Investors also form their own opinion of Contineum Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Contineum Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Contineum Therapeutics,'s market value can be influenced by many factors that don't directly affect Contineum Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Contineum Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Contineum Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Contineum Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.